Forty-nine patients with metastatic nonanaplastic thyroid carcinoma were treated over a 10-year period. Five successive chemotherapeutic protocols were used: a combination of doxorubicin, etoposide, 5-fluorouracil and cyclophosphamide; elliptinium acetate; doxorubicin; cispiatin; and the combination of doxorubicin and cispiatin. Results obtained with the different protocols were very disappointing, with only two objective responses (3%). Phase II trials with new chemotherapeutic agents are warranted in selected cases of nonanaplastic metastatic thyroid carcinoma.
Get full access to this article
View all access options for this article.
References
1.
Alexieva-FigushJ., Van GilseH.A., TreurnietR.E.: Chemotherapy in carcinoma of the thyroid: retrospective and prospective. Ann. Radiol., 20: 810–813, 1977.
2.
BurowskiR.M., BrownL., WeickI.K., GroppeC.W., PurvisJ.: Combination chemotherapy of metastatic thyroid cancer. Am. J. Clin. Oncol., 6: 579–581, 1983.
3.
DrozJ.P., CharbordP., RougierPh., ParmentierC.: Echec de la chimiothérapie des cancers de la thyroide. Bull. Cancer, 68: 350–352, 1981.
4.
DrozJ.P., RougierPh., GodefroyW., SchlumbergerM., GardetP., ParmentierC.: Chimiothérapie des cancers médullaires de la thyroide. Essai Phase II avec l'Adriamycine et le Cisplatinum administrés en monochimiothérapie. Bull. Cancer, 71: 195–199, 1984.
5.
DrozJ.P., MorardetN., CharbordP., MaraninchiD., HayatM., ParmentierC.: Chemotherapy of differentiated thyroid carcinomas. Clinical results and effects on the granulocytic stem cell (CFUc) compartment. Ann. Radiol., 20: 814–818, 1977.
6.
DrozJ.P., ParmentierS., MorardetN., MaraninchiD., GardetP., TubianaM.: Effects of radiotherapy on the bone marrow granulocytic progenitor cells (CFUc) of patients with malignant lymphomas. Int. J. Radiat. Oncol. Biol. Phys, 4: 845–851, 1978.
7.
GottliebJ.A., HillS.C.Jr.: Adriamycin (NSC-123127) therapy in thyroid cancer. Cancer Chemother. Rep., 6: 283–296, 1975.
8.
HedingerC., SobinL.H.: Histological typing of thyroid tumors n. 11.World Health Organisation, Geneva, 1974.
9.
HigbyD.J., WallaceH.J., AlbertD.J., HollandJ.F.: Diam-minodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer, 33: 1219–1225, 1974.
HusainM., AlseverR.N., LockJ.P., GeorgeW.F., KartzF.H.: Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Hormone Res., 9: 22–25, 1978.
12.
KalamakarP., FreemanA., HigbyD.J., WallaceH.J., SinksL.F.: Clinical response and toxicity with cis-dichlorodiam-mineplatinum (II) in children. Cancer Treat. Rep., 61: 835–839, 1977.
13.
LeclercqJ.B., Dat-XuongN., GosseC., PaolettiC.: A new antitumoral agent: 9-hydroxy-ellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc. Natl. Acad. Sci. USA, 71: 5078–5082, 1974.
14.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
PosterD.S., BrunoS., PentaJ., PinaK., CataneR.: Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin. Trials, 4: 301–307, 1981.
17.
ReyesJ., ShimaokaK.: Chemotherapy of thyroid carcinoma. Proc. Am. Assoc. Cancer Res. of Am. Soc. Clin. Oncol., 16: 229, 1975.
SamoniggH., HossfeldD.K., SpehnJ., FillH., LebG.: Aclarubicin in advanced thyroid cancer. A phase II study. Eur. J. Cancer Clin. Oncol., 24: 1271–1275, 1988.
20.
SchlumbergerM., ParmentierC.: Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer. Bull Cancer (Paris), 76: 403–406, 1989.
21.
SchlumbergerM., TubianaM., De VathaireF., HillC., GardetP., TravagliJ.P., FraguP., LumbrosoJ., CaillouB., ParmentierC.: Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 63: 960–967, 1986.
22.
ShimaokaK.: Adjunctive management of thyroid cancer: chemotherapy. J. Surg. Oncol., 15: 283–286, 1980.
23.
ShimaokaK., SchoenfeldD.A., DewysW.D., CreechR.H., de ContiR.: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer, 56: 2155–2160, 1985.
TubianaM., SchlumbergerM., RougierP., LaplancheA., BenhamouE., GardetP., CaillouB., TravagliJ.P., ParmentierC.: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer, 55: 794–804, 1985.
26.
WilliamsS.D., BirchR., EinhornL.H.: Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep., 70: 405–407, 1986.
